Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

The HPV-16 E7 oncoprotein binds Skip and suppresses its transcriptional activity

Abstract

E7 is the major transforming protein of human papillomavirus (HPV), which is implicated in the development of cervical cancer. The transforming activity of E7 has been attributed in part to its interaction with the retinoblastoma (Rb) tumour suppressor; however, the Rb interaction alone is not sufficient for transformation by E7. In a screen for cellular targets of HPV E7, we identified the Ski interacting protein, Skip, as a new interacting partner of E7. We show that HPV-16 E7 associates with Skip via sequences in its carboxy terminal region, and the evolutionarily conserved proline rich sequences (PRS) of the SNW domain of Skip. E7 functionally targets Skip in vivo and inhibits its transcriptional activation activity. Two transformation defective mutants of E7 were identified that failed both to bind Skip and to inhibit its transcriptional activity. These results suggest that inhibition of Skip function may contribute to cell transformation by HPV-16 E7.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8

Similar content being viewed by others

References

  • Androphy E, Hubbert N, Schiller J, Lowy D . 1987 EMBO J. 6: 989–992

  • Banks, L, Edmonds C, Vousden KH . 1990 Oncogene 5: 1383–1389

  • Banks L, Spence P, Androphy E, Hubbert N, Matlashewski G, Murray A, Crawford L . 1987 J. Gen. Virol. 68: 1351–1359

  • Barbosa M, Edmonds C, Fischer C, Schiller JT, Lowy D, Vousden K . 1990 EMBO J. 9: 153–160

  • Baudino TA, Kraichely DM, Jefcoat SC, Winchester SK, Partridge NC, MacDonald PN . 1998 J. Biol. Chem. 273: 16434–16441

  • Caldeira S, de Velliers EM, Tommasino M . 2000 Oncogene 19: 821–826

  • Chellappan S, Kraus VB, Kroger B, Münger K, Howley PM, Phleps WC, Nevins JR . 1992 Proc. Natl. Acad. Sci. USA 89: 4549–4553

  • Dahl R, Wani B, Hayman MJ . 1998 Oncogene 16: 1579–1586

  • Durfee T, Becherer K, Chen PL, Yeh SH, Yang Y, Kilburn AE, Lee WH, Elledge SJ . 1993 Genes Dev. 7: 555–569

  • Dyson N, Howley PM, Munger K, Harlow E . 1989 Science 243: 934–936

  • Edmonds C, Vousden K . 1989 J. Virol. 63: 2650–2656

  • Hawley-Nelson P, Vousden K, Hubbert N, Lowy D, Schiller J . 1989 EMBO J. 8: 3905–3910

  • Jansen-Dürr P . 1996 Trends Genet. 12: 270–275

  • Jewers RJ, Hildebranadt P, Ludlow JW, Kell B, McCance DJ . 1992 J. Virol. 66: 1329–1335

  • Kühne C, Banks L . 1998 J. Biol. Chem. 273: 34302–34309

  • Luckow B, Schutz G . 1987 Nucleic Acids Res. 15: 5490

  • Massimi P, Pim D, Banks L . 1997 J. Gen. Virol. 78: 2601–2613

  • Münger K, Phelps WC, Bubb V, Howley PM, Schlegel R . 1989 J. Virol. 63: 4417–4421

  • Murthy SC, Bhat GP, Thimmappaya B . 1985 Proc. Natl. Acad. Sci. USA 82: 2230–2234

  • Phelps WC, Yee CL, Münger K, Howley PM . 1988 Cell 53: 539–547

  • Pim D, Storey A, Thomas M, Massimi P, Banks L . 1994 Oncogene 9: 1869–1876

  • Prathapam T, Kühne C, Hayman M, Banks L . 2001 Nucleic Acids Res. 29: 3469–3476

  • Quin XQ, Chittenden T, Livingston DM, Kaelin Jr WG . 1992 Genes Dev. 6: 953–964

  • Sanger F, Nicklen S, Coulson AR . 1977 Proc. Natl. Acad. Sci. USA 74: 5463

  • Smotkin D, Wettstein F . 1986 Proc. Natl. Acad. Sci. USA 83: 4680–4684

  • Stavnezer E, Gerhard DS, Binari C, Balzas I . 1981 J. Virol. 39: 920–934

  • Storey A, Pim D, Murray A, Osborn K, Banks L, Crawford L . 1988 EMBO J. 7: 1815–1820

  • Tokitou F, Nomura T, Khan MM, Kaul SC, Wadhwa R, Yasukawa T, Kohno I, Ishii S . 1999 J. Biol. Chem. 274: 4485–4488

  • Watanabe S, Kanda T, Yoshiike K . 1990 J. Virol. 64: 207–214

  • Werness BA, Levine AJ, Howley PM . 1990 Science 248: 76–79

  • Zhou S, Fujimuro M, Hsieh JJ-D, Chen L, Hayward SD . 2000 J. Virol. 74: 1939–1947

  • zur Hausen H, Schneider A . 1987 In: Salzman, NP, Howley, PM (eds). The papillomaviruses Plenum Publishing Corp.: New York pp 245–263

Download references

Acknowledgements

We are very grateful to Paola Massimi and David Pim for the Δ52–56 E7 mutant and their help and advice. We are also very grateful to Mike Hayman for his gift of pCGSP-Skip and pMT2-Ski expression plasmids. We would like to thank Gianni del Sal for the pRb expression construct and Mauro Sturnega for the help in the production of antibodies. We would also like to thank Miranda Thomas for her comments on the manuscript. This work was supported in part by research grants from the Associazione Italiana per la Ricerca Sul Cancro and the EU Biomed 2 program.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Prathapam, T., Kühne, C. & Banks, L. The HPV-16 E7 oncoprotein binds Skip and suppresses its transcriptional activity. Oncogene 20, 7677–7685 (2001). https://doi.org/10.1038/sj.onc.1204960

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1204960

Keywords

This article is cited by

Search

Quick links